Meeting
2022 ASCO Annual Meeting
Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.
Authors
Sandra P. D'Angelo
Memorial Sloan Kettering Cancer Center, New York, NY
Sandra P. D'Angelo , Steven Attia , Jean-Yves Blay , Sandra J. Strauss , Claudia Maria Valverde Morales , Albiruni Ryan Abdul Razak , Erin Van Winkle , Thejo Annareddy , Chandra Sattigari , Evangelo Diamantopoulos , Dennis Williams , Elliot Norry , Swethajit Biswas , Dejka M. Araujo , Brian Andrew Van Tine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04044768, NCT03132922
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11562)
DOI
10.1200/JCO.2022.40.16_suppl.11562
Abstract #
11562
Poster Bd #
466
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
First Author: Dejka M. Araujo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA).
First Author: E. Gabriela Chiorean
Poster
2022 ASCO Annual Meeting
A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.
First Author: Scott Kopetz